Elimusertib (BAY1895344)

DRUG3 trials

Sponsors

Bayer

Conditions

Advanced Solid TumorAdvanced Solid TumorsAdvanced Solid Tumors (Excluding Prostate Cancer)Mantle Cell LymphomaNon-Hodgkin's LymphomaOvarian Cancer

Phase 1

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

CompletedNCT03188965

BayerAdvanced Solid Tumor, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma

Start: 2017-07-06End: 2023-09-13Updated: 2023-10-11

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

CompletedNCT04095273

BayerAdvanced Solid Tumors

Start: 2019-09-30End: 2023-04-11Updated: 2024-04-02

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

TerminatedNCT04267939

BayerAdvanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer

Start: 2020-02-26End: 2023-12-01Updated: 2023-12-21

Related Papers

Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Cancer Research2023-04-04

EP294/#883 Elimusertib, an oral ataxia telangiectasia and RAD3-related inhibitor, in advanced gynecologic cancers with DNA damage response defects

E-Posters2022-12-011 citations

Abstract CT006: Phase Ib expansion trial of the safety and efficacy of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor elimusertib in advanced solid tumors with DNA damage response (DDR) defects

Cancer Research2022-06-1512 citations

Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma.

Journal of Clinical Oncology2022-06-015 citations

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Journal of Medicinal Chemistry2020-06-0568 citations

Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

Cancer Research2019-07-014 citations

Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures

Cancer Research2019-07-013 citations

Abstract 272: Synergistic activity of the ATR inhibitor BAY1895344 in combination with immune checkpoint inhibitors in preclinical tumor models

Experimental and Molecular Therapeutics2019-07-01

Abstract 274: The ATR inhibitor BAY 1895344 shows strong preclinical activity in lymphomas and appears associated with specific gene expression signatures

Experimental and Molecular Therapeutics2019-07-01

First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2019-05-2030 citations

Abstract 838: Synergistic <i>in vivo</i> activity of the ATR inhibitor BAY 1895344 in combination with the targeted alpha therapy radium-223 dichloride in a preclinical tumor model mimicking bone metastatic castration-resistant prostate cancer (mCRPC)

Cancer Research2018-07-016 citations

Abstract 321: Synergistic activity of the ATR inhibitor BAY 1895344 in combination with DNA damage inducing and DNA repair compromising therapies in preclinical tumor models

Cancer Research2018-07-013 citations